(Q32044975)

English

Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

author name string

Badger AM

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Blake S

2

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Kapadia R

3

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Sarkar S

4

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Levin J

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Swift BA

6

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Hoffman SJ

7

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Stroup GB

8

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Miller WH

9

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Gowen M

10

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Lark MW

11

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

128-137

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

The alpha v beta 3 integrin "vitronectin receptor"

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

Integrins on rat osteoclasts: characterization of two monoclonal antibodies (F4 and F11) to rat beta 3

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

The integrin alphavbeta5 is expressed on avian osteoclast precursors and regulated by retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF).

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C128%3A%3AAID-ANR17%3E3.0.CO%3B2-M

21 January 2018

Identifiers

10.1002/1529-0131(200101)44:1<128::AID-ANR17>3.0.CO;2-M

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q32044975&oldid=1634898327"